AIM: To determine the effectiveness of treatment with immunosuppressive drugs and monoclonal antibodies (mAb) after penetrating keratoplasty in two different models of high risk mouse recipients. METHODS: Corneas were grafted orthotopically in mouse models of high risk recipients with either neovascularisation of the graft bed or presensitisation to graft donor antigens. Recipients were treated with mAb against CD4(+) or CD8(+) cells or against T cells, or were treated with cyclosporin A (CsA) or mycophenolate mofetil (MMF), or a combination of both drugs. RESULTS: Control untreated recipients with neovascularised graft bed or presensitised to the graft donor antigens rejected corneal allografts in 12.5 (SD 2.3) and 9.9 (1.6) days, respectively. Treatment of graft recipients with a neovascularised graft bed with mAb anti-CD4 or anti-T cells, but not with mAb anti-CD8 or with immunosuppressive drugs, resulted in a significant prolongation of graft survival; 75% and 28.5%, respectively, of grafts survived for more than 45 days after grafting. However, none of the treatments were successful in presensitised recipients. CONCLUSIONS: Treatment of high risk recipients with mAb anti-CD4 is more effective in preventing corneal allograft rejection than the treatment with mAb anti-CD8 or the immunosuppressive drugs MMF and CsA. However, the effectiveness of the treatment depends on the recipients' pretransplantation risk type.

Institute of Molecular Genetics Academy of Sciences Flemingovo nám 2 166 37 Prague 6 Czech Republic

Zobrazit více v PubMed

Williams KA, Muehlberg SM, Lewis RF, et al. The Australian corneal graft registry 1996 report. Adelaide: Mercury Press, 1997;11:47–50.

Williams KA, Muehlberg SM, Lewis RF, et al. Long-term outcome in corneal allotransplantation. Transplant Proc 1997;29:983. PubMed

Kuffová L, Holáň V, Lumsden L, et al. Cell subpopulations in failed human corneal grafts. Br J Ophthalmol 1999;83:1364–9. PubMed PMC

Larkin DF, Alexander RA, Cree IA. Infiltrating inflammatory cell phenotypes and apoptosis in rejected human corneal allografts. Eye 1997;11:68–74. PubMed

Kuffová L, Lumsden L, Veselá V, et al. Kinetics of leukocyte and myeloid cell traffic in the murine corneal allograft response. Transplantation 2001;72:1292–8. PubMed

Larkin DF, Calder VL, Lightman SL. Identification and characterization of cells infiltrating the graft and aqueous humour in rat corneal allograft rejection. Clin Exp Immunol 1997;107:381–91. PubMed PMC

Veen GV, Broersma L, Dijkstra CD, et al. Prevention of corneal allograft rejection in rats treated with subconjunctival injections of liposomes containing dichloromethylene diphosphonate. Invest Ophthalmol Vis Sci 1994;35:3505–15. PubMed

Krulová M, Zajícová A, Frič J, et al. Alloantigen-induced, T-cell-dependent production of nitric oxide by macrophages infiltrating skin allografts in mice. Transplant Int 2002;15:108–16. PubMed

Ayliffe W, Alam Y, Bell EB, et al. Prolongation of rat corneal graft survival by treatment with anti-CD4 monoclonal antibody. Br J Ophthalmol 1992;76:602–6. PubMed PMC

He YG, Ross J, Niederkorn JY. Promotion of murine orthotopic corneal allograft survival by systemic administration of anti-CD4 monoclonal antibody. Invest Ophthalmol Vis Sci 1991;32:2723–8. PubMed

Thiel MA, Takano T, Hawksworth N, et al. Low-dose, short-term treatment with anti-CD4 monoclonal antibody prolongs corneal allograft survival. Transplant Proc 2001;33:635–6. PubMed

Pleyer U, Milani JK, Dukes A, et al. Effect of topically applied anti-CD4 monoclonal antibodies on orthotopic corneal allografts in a rat model. Invest Ophthalmol Vis Sci 1995;36:52–61. PubMed

Ippoliti G, Fronterre A. Use of locally injected anti-T monoclonal antibodies in the treatment of acute corneal graft rejection. Transplant Proc 1987;19:2579–80. PubMed

Ippoliti G, Fronterre A. Usefulness of CD3 or CD6 anti-T monoclonal antibodies in the treatment of acute corneal graft rejection. Transplant Proc 1989;21:3133–4. PubMed

Newman DK, Isaacs JD, Watson PG, et al. Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, Campath-1H. Eye 1995;9:564–9. PubMed

Dick AD, Meyer P, James T, et al. Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 2000;84:107–9. PubMed PMC

Schmitz K, Hitzer S, Behrens-Baumann W. Immune suppression by combination therapy with basiliximab and cyclosporin in high risk keratoplasty. A pilot study. Ophthalmology 2002;99:38–45. PubMed

Reis A, Reinhard T, Voiculescu A, et al. Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: prospectively randomised clinical trial. Br J Ophthalmol 1999;83:1268–71. PubMed PMC

Reinhard T, Reis A, Bohringer D, et al. Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years’ results of a randomized prospective clinical trial. Graefes Arch Clin Exp Ophthalmol 2001;239:367–72. PubMed

Soares-Wulf A, Aboalchamat B, Krüger R, et al. Long-term results of immunosuppressive therapy with mycophenolate mofetil (CellCept) for keratoplasty in high-risk patients. Invest Ophthalmol Vis Sci 2002;43 E-Abstract 2241.

Poon AC, Forbes JE, Dart JKG, et al. Systemic cyclosporin A in high risk penetrating keratoplasties: a case-control study. Br J Ophthalmol 2001;85:1464–9. PubMed PMC

She SC, Steahly LP, Moticka EJ. A method for performing full-thickness, orthotopic, penetrating keratoplasty in the mouse. Ophthalmic Surg 1990;21:781–5. PubMed

Plšková J, Duncan L, Holáň V, et al. The immune response to corneal allograft requires a site-specific draining lymph node. Transplantation 2002;73:210–15. PubMed

Plšková J, Kuffová L, Holáň V, et al. Evaluation of corneal graft rejection in a mouse model. Br J Ophthalmol 2002;86:108–13. PubMed PMC

Lake P, Clark EA, Khorshidi M, et al. Production and characterization of cytotoxic Thy-1 antibody-secreting hybrid cell lines. Detection of T cell subsets. Eur J Immunol 1979;9:875–86. PubMed

Dialynas DP, Wilde DB, Marrack P, et al. Characterization of the murine antigenic determinant designated L3T4a, recognized by monoclonal antibody GK1.5: expression of L3T4a by functional T-cell clones appears to correlate primarily with class II MHC antigen-reactivity. Immunol Rev 1983;74:29–56. PubMed

Gottlieb PD, Marshak-Rothstein A, Auditore-Hargreaves K, et al. Construction and properties of new Lyt-congeneic strains and anti-Lyt-2.2 and anti-Lyt-3.1 monoclonal antibodies. Immunogenetics 1980;10:545–52. PubMed

Reis A, Reinhard T, Sundmacher R, et al. Effect of mycophenolate mofetil, cyclosporin A, and both in combination in a murine corneal graft rejection model. Br J Ophthalmol 1998;82:700–3. PubMed PMC

Reis A, Megahed M, Reinhard T, et al. Coadministration of the new macrolide immunosuppressant RAD and mycophenolate mofetil in experimental corneal transplantation. Transplantation 2000;70:1397–407. PubMed

Shepherd WF, Coster DJ, Fook TC, et al. Effect of cyclosporine A on the survival of corneal grafts in rabbits. Br J Ophthalmol 1980;64:148–53. PubMed PMC

Coster DJ, Shepard WFI, Chin Fook T, et al. Prolonged survival of corneal allografts in rabbits treated with cyclosporine A. Lancet 1979;2:688–9. PubMed

Hill JC, Maske R. An animal model for corneal graft rejection in high risk keratoplasty. Transplantation 1988;46:26–30. PubMed

Rehany U, Waisman M. Suppression of corneal allogtaft rejection by systemic cyclosporine-A in heavily vascularized rabbit corneas following alkali burns. Cornea 1994;13:447–53. PubMed

Yamada J, Kurimoto I, Streilein W. Role of CD4+ T cells in immunobiology of orthotopic corneal transplants in mice. Invest Ophthalmol Vis Sci 1999;40:2614–21. PubMed

Boisgérault F, Liu Y, Anosova N, et al. Role of CD4+ and CD8+ T cells in allorecognition: Lessons from corneal transplantation. J Immunol 2001;167:1891–9. PubMed

Hedge S, Niederkorn JY. The role of cytotoxic T lymphocytes in corneal allograft rejection. Invest Ophthalmol Vis Sci 2000;41:3341–7. PubMed

Yamada J, Ksander BR, Streilein JW. Cytotoxic T cells play no essential role in acute rejection of orthotopic corneal allografts in mice. Invest Ophthalmol Vis Sci 2001;42:386–92. PubMed